Inter-Institutional Biological and Recombinant DNA Safety Committee (IBRDSC)

The Inter-Institutional Biological and Recombinant DNA Safety Committee (IBRDSC), often times also called the Institutional Biosafety Committee or IBC, reviews, approves and oversees research, teaching and diagnostics involving the use of recombinant or synthetic nucleic acids and other biohazards. The IBRDS committee is charged with protecting LSU faculty, students, staff, and visitors and has the authority to stop any activity that the committee believes to be unsafe.

The National Institutes of Health (NIH) mandates that LSU establish and maintain an Institutional Biosafety Committee for review and approval of all research involving recombinant DNA and biohazards. The committee follows Federal guidelines with respect to the review and approval of protocols.  Activities that require approve approval include procurement, use, storage, transportation, and disposal of biohazardous material. 

What You Need to Know

IBRDSC meetings are open to the public and are held virtually once a month.  Meeting dates and times are subject to change based on the availability of the committee members. 

The IBRDSC reviews the Biological Safety Registration Document submitted virtually during their monthly meetings.  Incomplete or documents missing critical information are subject to being put "On Hold" until such a time as the relevant information is obtained. Associated work is prohibited until the Biological Safety Document is approved by the committee. The deadline for submission for review at a meeting is one week prior to the meeting by 4:00 p.m.  Registration documents submitted after 4:00 p.m. will be reviewed at the meeting the following month.  

Meeting minutes may be provided upon written request. 

2024 IBRDSC Meeting Dates

Additional Information

If you need additional information or have questions about the registration process, please visit the Biological Research Approval page or contact Dr. Abigail Fish at afish5@lsu.edu 

• IBRDSC Charter and Policies
• Dual Use Research
• NIH FAQs on Institutional Biosafety Committees